Journal of Clinical Oncology
Articles in this Issue
Trends and disparities in laryngeal carcinoma–related mortality among adults in the United States from 1999 to 2023: A nationwide analysis.
e18039 Background: Laryngeal carcinoma-related mortality trends are influenced by access to early diagnosis and treatment making it a public health concer...
Growing burden of cancer and high body mass index in the United States from 1990-2021: A benchmarking cross-state analysis.
10528 Background: Cancer (CA) remains a major public health challenge and is the second leading cause of death and disability in the United States. Among...
Molecular profiling in NSCLC: Uncovering disparities and advancing health equity.
e22599 Background: Non-small cell lung cancer (NSCLC) comprises 85% of lung cancer cases, including squamous-cell carcinoma, adenocarcinoma, and large-cel...
Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.
1516 Background: Paucity of data on breast cancer (BC) in transgender, nonbinary, and gender-diverse (TGD) individuals leads to suboptimal screening and t...
Decoding spatial transcriptomics-based heterogeneity of TME in early-stage invasive pulmonary adenocarcinoma.
e20030 Background: Tumoral heterogeneity has been widely acknowledged to influence clinical outcome of lung adenocarcinoma (LUAD). This study investigated...
Outcomes with imetelstat in myelofibrosis: A systematic review and meta-analysis.
e18593 Background: Myelofibrosis (MF) patients who progressed on Janus Kinase inhibitors (JAKi), and are ineligible for allogeneic stem cell transplant ha...
Racial disparities in mammogram rates across Texas in 2022: A statewide analysis.
e22511 Background: Breast cancer is the second leading cause of cancer death among women in the United States, and its incidence has been steadily increas...
Association between pretreatment emotional distress and survival outcomes in patients with advanced non–small-cell lung cancer: An individual patient data meta-analysis of 4632 patients in 7 trials.
8546 Background: Emotional distress (ED) associated with worse survival outcomes in patients with melanoma and non-small-cell lung cancer treated with imm...
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).
TPS8670 Background: The introduction of immune checkpoint inhibition for the treatment of 1L NSCLC has improved survival, however long-term outcomes remai...
A multi-omics approach using lipids and proteins for early detection in individuals with signs and symptoms of ovarian cancer.
5581 Background: Late-stage ovarian cancer (OC) is diagnosed in 80% of patients, leading to a five-year survival rate below 30% and ranking OC as the fift...
panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with <i>HER2</i> -activating mutations.
TPS3185 Background: Human epidermal growth factor receptor 2 ( HER2 ) gene mutations occur in approximately 3.5% of solid tumors,...
Association between fine particulate matter exposure and colorectal cancer mortality by age at diagnosis: Insights from county-level analysis in the United States.
3632 Background: Colorectal cancer (CRC) remains a leading cause of cancer mortality in the U.S., with environmental factors like air pollution potentiall...
Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal (GEJ) adenocarcinoma (AC): A network meta-analysis.
e16157 Background: The optimal treatment for resectable gastric/GEJ AC is unclear due to limited direct comparisons among chemotherapy and chemoradiation...
Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy.
e20555 Background: Molecular profiling is inconsistently performed in patients with mLUSC as it rarely provides actionable information. Whether it can aid...
Accelerating phase 2 clinical development with real-world data (RWD): An external control arm (ECA) pilot in HER2-positive (HER2+) metastatic breast cancer (mBC).
11172 Background: Accelerating clinical development of promising therapies is essential to improving patient (pt) outcomes. While ECAs have provided valua...
Growth recovery in patients with <i>BRAF</i> altered pediatric low-grade gliomas (LGG) after discontinuation of tovorafenib.
10029 Background: Tovorafenib is a selective, CNS-penetrant, type II RAF inhibitor that targets BRAF and CRAF. Based on preclinical data, CRAF plays an es...
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, in patients with advanced solid tumors.
TPS2668 Background: NY-ESO-1 and LAGE-1 are homologous proteins commonly expressed in various malignancies but not in normal tissues other than the testis...
Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort.
11177 Background: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but life-threatening immune-related adverse event (irAE), with a mort...
Immune checkpoint inhibitors in lung cancer: A retrospective cohort analysis of cardiovascular safety profiles.
e20069 Background: Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment, providing significant clinical benefits. However, they a...
Effect of body mass index on the prognostic impact of progesterone receptor in postmenopausal ER+HER2- breast cancer: A nationwide study in Korean Breast Cancer Society and multi-institutional cohort.
e12541 Background: Obesity, a known risk factor for breast cancer, is associated with increased estrogen levels in postmenopausal women, which can stimula...
KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer.
TPS8652 Background: A standard-of-care option for metastatic non–small-cell lung cancer (NSCLC) with no targetable genetic alterations includes pembrolizu...
Resistance mutations in lung cancer: A perspective from the Mexican population.
e20531 Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide, with one of the lowest survival rates, representing the 7th c...
Monocentric pilot trial of trametinib in severe extracranial arteriovenous malformations.
3096 Background: The Mitogen Activated Protein Kinase (MAPK) pathway is crucial for cell growth, proliferation, and survival. Overactivation of MAPK is ob...
Comparison of coronary artery calcification in breast cancer survivors with age matched controls: A prospective case-control study.
e24017 Background: Breast cancer (BC) is curable when detected in early stages with the help of multi-modality treatment. However, the Breast cancer survi...
KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype.
4547 Background: KEAP1 is a tumor suppressor and negative regulator of the NRF2 pathway, and inactivating KEAP1 mutations (mts) ha...